|
Volumn 23, Issue 5, 2015, Pages 355-357
|
Challenges, progresses, and promises for developing future NADPH oxidase therapeutics
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ARACHIDONIC ACID;
OXIDOREDUCTASE INHIBITOR;
REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;
REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1;
REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2;
REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4;
REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE INHIBITOR;
UNCLASSIFIED DRUG;
HV1 CHANNEL, HUMAN;
ION CHANNEL;
CHEMICAL STRUCTURE;
CHRONIC INFLAMMATION;
DISEASE MARKER;
DRUG INDUSTRY;
ENZYME ACTIVITY;
ENZYME INHIBITION;
EXTRACELLULAR SPACE;
HUMAN;
IMMUNE DEFICIENCY;
NONHUMAN;
OXIDATIVE STRESS;
PRIORITY JOURNAL;
PULMONARY HYPERTENSION;
REPERFUSION INJURY;
RESPIRATORY BURST;
REVIEW;
STRATIFICATION;
ANIMAL;
DRUG DEVELOPMENT;
METABOLISM;
ANIMALS;
DRUG DISCOVERY;
HUMANS;
ION CHANNELS;
NADPH OXIDASE;
OXIDATIVE STRESS;
|
EID: 84939439634
PISSN: 15230864
EISSN: 15577716
Source Type: Journal
DOI: 10.1089/ars.2015.6450 Document Type: Review |
Times cited : (14)
|
References (8)
|